|
1
|
Bernier J: Precision medicine for early
breast cancer radiotherapy: Opening up new horizons? Crit Rev Oncol
Hematol. 113:79–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bennett MH, Feldmeier J, Smee R and
Milross C: Hyperbaric oxygenation for tumour sensitisation to
radiotherapy. Cochrane Database Syst Rev. 11:CD0050072012.
|
|
3
|
Schütze A, Vogeley C, Gorges T, Twarock S,
Butschan J, Babayan A, Klein D, Knauer SK, Metzen E, Müller V, et
al: RHAMM splice variants confer radiosensitivity in human breast
cancer cell lines. Oncotarget. 7:21428–21440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang RX and Zhou PK: DNA damage response
signaling pathways and targets for radiotherapy sensitization in
cancer. Signal Transduct Target Ther. 5:602020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai Y, Yu X, Lin X and He S: Inhibition of
mTOR sensitizes breast cancer stem cells to radiation-induced
repression of self-renewal through the regulation of MnSOD and Akt.
Int J Mol Med. 37:369–377. 2016. View Article : Google Scholar :
|
|
6
|
Silvera D, Formenti SC and Schneider RJ:
Translational control in cancer. Nat Rev Cancer. 10:254–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peretz S, Jensen R, Baserga R and Glazer
PM: ATM-Dependent expression of the insulin-like growth factor-I
receptor in a pathway regulating radiation response. Proc Natl Acad
Sci USA. 98:1676–1681. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo YM, Xia NX, Yang L, Li Z, Yang H, Yu
HJ, Liu Y, Lei H, Zhou FX, Xie CH, et al: CTC1 increases the
radioresistance of human melanoma cells by inhibiting telomere
shortening and apoptosis. Int J Mol Med. 33:1484–1490. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dolman MEM, van der Ploeg I, Koster J,
Bate-Eya LT, Versteeg R, Caron HN and Molenaar JJ: DNA-Dependent
protein kinase as molecular target for radiosensitization of
neuroblastoma cells. PLoS One. 10:e01457442015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rachmadi L, Siregar NC, Kanoko M,
Andrijono A, Bardosono S, Suryandari DA, Sekarutami SM and Hernowo
BS: Role of cancer stem cell, apoptotic factor, DNA repair, and
telomerase toward radiation therapy response in stage IIIB cervical
cancer. Oman Med J. 34:224–230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu CC, Huang H, Hung SK, Liao HF, Lee CC,
Lin HY, Li SC, Ho HC, Hung CL and Su YC: AZD2014 radiosensitizes
oral squamous cell carcinoma by inhibiting AKT/mTOR axis and
inducing G1/G2/M cell cycle arrest. PLoS One. 11:e01519422016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gewirtz DA: The four faces of autophagy:
Implications for cancer therapy. Cancer Res. 74:647–651. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khoshinani HM, Afshar S and Najafi R:
Hypoxia: A double-edged sword in cancer therapy. Cancer Invest.
34:536–545. 2016. View Article : Google Scholar
|
|
14
|
Saenko YV, Mastilenko AV, Glushchenko ES,
Antonova AV and Svekolkin VP: Inhibition of mitochondrial
voltage-dependent anion channels increases radiosensitivity of K562
leukemic cells. Bull Exp Biol Med. 161:104–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baro M, Sambrooks CL, Quijano A, Saltzman
WM and Contessa J: Oligosaccharyltransferase inhibition reduces
receptor tyrosine kinase activation and enhances glioma
radiosensitivity. Clin Cancer Res. 25:784–795. 2019. View Article : Google Scholar :
|
|
16
|
Segawa T, Fujii Y, Tanaka A, Bando SI,
Okayasu R, Ohnishi K and Kubota N: Radiosensitization of human lung
cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Int J Mol Med. 33:559–564. 2014. View Article : Google Scholar
|
|
17
|
Zhang L, Yoo S, Dritschilo A, Belyaev I
and Soldatenkov V: Targeting ku protein for sensitizing of breast
cancer cells to DNA-damage. Int J Mol Med. 14:153–159.
2004.PubMed/NCBI
|
|
18
|
Zhang F, Fan B and Mao L: Radiosensitizing
effects of cyclocarya paliurus polysaccharide on hypoxic A549 and
H520 human non-small cell lung carcinoma cells. Int J Mol Med.
44:1233–1242. 2019.PubMed/NCBI
|
|
19
|
Chang L, Graham PH, Hao J, Ni J, Bucci J,
Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors
enhance radiosensitivity in radioresistant prostate cancer cells
through inducing apoptosis, reducing autophagy, suppressing NHEJ
and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boguski MS, Mandl KD and Sukhatme VP: Drug
discovery. Repurposing with a difference Science. 324:1394–1395.
2009.
|
|
21
|
Rasheed S, Sánchez SS, Yousuf S, Honoré SM
and Choudhary MI: Drug repurposing: In-vitro anti-glycation
properties of 18 common drugs. PLoS One. 13:e01905092018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amsberg GK and Schafhausen P: Bosutinib in
the management of chronic myelogenous leukemia. Biologics.
7:115–122. 2013.PubMed/NCBI
|
|
23
|
Amsberg GKV and Brümmendorf TH: Novel
aspects of therapy with the dual src and abl kinase inhibitor
bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther.
12:1121–1127. 2012. View Article : Google Scholar
|
|
24
|
Lee JH, Choi SI, Kim RK, Cho EW and Kim
IG: Tescalcin/c-Src/IGF1Rβ-mediated STAT3 activation enhances
cancer stemness and radioresistant properties through ALDH1. Sci
Rep. 8:107112018. View Article : Google Scholar
|
|
25
|
Cammarata FP, Torrisi F, Forte GI, Minafra
L, Bravatà V, Pisciotta P, Savoca G, Calvaruso M, Petringa G,
Cirrone GA, et al: Proton therapy and src family kinase inhibitor
combined treatments on U87 human glioblastoma multiforme cell line.
Int J Mol Sci. 20:47452019. View Article : Google Scholar :
|
|
26
|
Badura M, Braunstein S, Zavadil J and
Schneider RJ: DNA damage and eIF4G1 in breast cancer cells
reprogram translation for survival and DNA repair mRNAs. Proc Natl
Acad Sci USA. 109:18767–18772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Keenan AB, Jenkins SL, Jagodnik KM, Koplev
S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A,
et al: The library of integrated network-based cellular signatures
NIH program: System-Level cataloging of human cells response to
perturbations. Cell Syst. 6:13–24. 2018. View Article : Google Scholar
|
|
28
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pfeffer RM: Radiotherapy for breast
cancer: Curing the cancer while protecting the heart. Isr Med Assoc
J. 20:582–583. 2018.PubMed/NCBI
|
|
31
|
Taylor CW and Kirby AM: Cardiac
side-effects from breast cancer radiotherapy. Clin Oncol (R Coll
Radiol). 27:621–629. 2015. View Article : Google Scholar
|
|
32
|
Tarpley M, Abdissa TT, Johnson GL and
Scott JE: Bosutinib reduces the efficacy of dasatinib in
triple-negative breast cancer cell lines. Anticancer Res.
34:1629–1635. 2014.PubMed/NCBI
|
|
33
|
Tan DSW, Haaland B, Gan JM, Tham SC, Sinha
I, Tan EH, Lim KH, Takano A, Krisna SS, Thu MM, et al: Bosutinib
inhibits migration and invasion via ACK1 in KRAS mutant non-small
cell lung cancer. Mol Cancer. 13:132014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wie SM, Wellberg E, Karam SD and Reyland
ME: Tyrosine kinase inhibitors protect the salivary gland from
radiation damage by inhibiting activation of protein kinase C-δ.
Mol Cancer Ther. 16:1989–1998. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wenzel T, Büch T, Urban N, Weirauch U,
Schierle K, Aigner A, Schaefer M and Kalwa H: Restoration of MARCKS
enhances chemosensitivity in cancer. J Cancer Res Clin Oncol.
146:843–858. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chou TC: Drug combination studies and
their synergy quantification using the chou-talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ellegaard AM, Groth-Pedersen L, Oorschot
V, Klumperman J, Kirkegaard T, Nylandsted J and Jäättelä M:
Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize
lysosomes, and inhibit multidrug resistance. Mol Cancer Ther.
12:2018–2030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Evelyn CR, Lisabeth EM, Wade SM, Haak AJ,
Johnson CN, Lawlor ER and Neubig RR: Small-Molecule inhibition of
Rho/MKL/SRF transcription in prostate cancer cells: Modulation of
cell cycle, er stress, and metastasis gene networks. Microarrays
(Basel). 5:132016. View Article : Google Scholar
|
|
39
|
Wainberg ZA, Alsina M, Soares HP, Braña I,
Britten CD, Conte GD, Ezeh P, Houk B, Kern KA, Leong S, et al: A
multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and
gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor
PD-0325901 in advanced cancer. Target Oncol. 12:775–785. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hamilton DG, Bale R, Jones C, Fitzgerald
E, Khor R, Knight K and Wasiak J: Impact of tumour bed boost
integration on acute and late toxicity in patients with breast
cancer: A systematic review. Breast. 27:126–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jaiswal PK, Koul S, Shanmugam PST and Koul
HK: Eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) is
upregulated during prostate cancer progression and modulates cell
growth and metastasis. Sci Rep. 8:74592018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gourd E: Bosutinib more effective than
imatinib in CML. Lancet Oncol. 18:e7162017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hu MB, Zhang JW, Gao JB, Qi YW, Gao Y, Xu
L, Ma Y and Wei ZZ: Atorvastatin induces autophagy in MDA-MB-231
breast cancer cells. Ultrastruct Pathol. 42:409–415. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chang CH, Bijian K, Wernic D, Su J, da
Silva SD, Yu H, Qiu D, Asslan M and Alaoui-Jamali MA: A novel
orally available seleno-purine molecule suppresses triple-negative
breast cancer cell proliferation and progression to metastasis by
inducing cytostatic autophagy. Autophagy. 15:1376–1390. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin SC, Chu PY, Liao WT, Wu MY, Tsui KH,
Lin LT, Huang CH, Chen LL and Li CJ: Glycyrrhizic acid induces
human MDA-MB-231 breast cancer cell death and autophagy via the
ROS-mitochondrial pathway. Oncol Rep. 39:703–710. 2018.
|
|
46
|
Noguchi S, Shibutani S, Fukushima K, Mori
T, Igase M and Mizuno T: Bosutinib, an SRC inhibitor, induces
caspase-independent cell death associated with permeabilization of
lysosomal membranes in melanoma cells. Vet Comp Oncol. 16:69–76.
2018. View Article : Google Scholar
|
|
47
|
Nam AR, Kim JW, Park JE, Bang JH, Jin MH,
Lee KH, Kim TY, Han SW, Im SA, Kim TY, et al: Src as a therapeutic
target in biliary tract cancer. Mol Cancer Ther. 15:1515–1524.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Weberpals J, Jansen L, Müller OJ and
Brenner H: Long-Term heart-specific mortality among 347 476 breast
cancer patients treated with radiotherapy or chemotherapy: A
registry-based cohort study. Eur Heart J. 39:3896–3903. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang R, Zhou Y, Hu S, Ren G, Cui F and
Zhou PK: Radiotherapy exposure in cancer patients and subsequent
risk of stroke: A systematic review and meta-analysis. Front
Neurol. 10:2332019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cortes JE, Khoury HJ, Kantarjian H,
Brümmendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD,
Dimitrov S, et al: Long-Term evaluation of cardiac and vascular
toxicity in patients with philadelphia chromosome-positive
leukemias treated with bosutinib. Am J Hematol. 91:606–616. 2016.
View Article : Google Scholar : PubMed/NCBI
|
